ASCO 2023

ASCO 2023
June 02-06, 2023
Chicago, IL

American Society of Clinical Oncology.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (15)

    ARC-7: Randomized Phase 2 Study of Domvanalimab + Zimberelimab +/- Etrumadenant vs Zimberelimab in First-Line, Metastatic, PD-L1-High Non-Small Cell Lung Cancer (NSCLC)

    • Author(s): Johnson, M
    • domvanalimab
    • Oncology
    • ARC-7
    • NSCLC
    • Dom
    • domvanalimab
    • Zim
    • zimberelimab
    • Etrumadenant
    • PD-L1 High

    Final Overall Survival Analysis from the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan in Patients with HR+/HER2- Metastatic Breast Cancer

    • Author(s): Tolaney, S
    • trodelvy
    • Oncology
    • OS
    • Survival
    • TROPiCS-02
    • SG
    • Sacituzumab
    • Trodelvy
    • HR+
    • HR+/HER2-

    A Phase 2 Study of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ELEVATE HNSCC) (TiP)

    • Author(s): Colevas, A
    • magrolimab
    • Oncology
    • Poster
    • Magro
    • magrolimab
    • ELEVATE
    • HNSCC

    TROPiCS-03, A Phase 2 Basket Study of Sacituzumab Govitecan in Patients with Metastatic Solid Tumors: Early Analysis in Patients with Advanced/Metastatic Endometrial Cancer

    • Author(s): Santin, A
    • trodelvy
    • Oncology
    • Poster
    • TROPiCs-03
    • SG
    • Sacituzumab
    • Trodelvy
    • solid tumors
    • endomedtiral cancer
    • EC
    • Basket

    STAR-221: A Randomized, Open-Label, Multicenter, Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Previously Untreated, Locally Advanced, Unresectable or Metastatic Gastric, Gastroesophageal Junction and

    • Author(s): Klempner, S
    • domvanalimab
    • Oncology
    • Poster
    • STAR-221
    • domvanalimab
    • zimberelimab
    • Gastric
    • Upper GI
    • Esophageal
    • Gastro

    Efficacy of Sacituzumab Govitecan in Locally Advanced or Metastatic Urothelial Cancer by Trophoblast Cell Surface Antigen 2 (Trop-2) Expression

    • Author(s): Loriot, Y
    • trodelvy
    • Oncology
    • Poster
    • SG
    • Sacituzumab
    • Trodelvy
    • mUC
    • Bladder Cancer
    • Trop-2

    ARC-10: A Phase 3 Study to Evaluate Zimberelimab + Domvanalimab versus Pembrolizumab in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non–Small Cell Lung Cancer

    • Author(s): Chouaid, C
    • domvanalimab
    • Oncology
    • Poster
    • ARC-10
    • NSCLC
    • Dom
    • domvanalimab
    • Zim
    • zimberelimab
    • Pembro
    • front line
    • PD-L1 High

    A Phase 2 Randomized Study of Magrolimab Combination Therapy in Adult Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE-TNBC) (TiP)

    • Author(s): Rainey, N
    • magrolimab
    • Oncology
    • Poster
    • Magro
    • magrolimab
    • mTNBC
    • TNBC
    • ELEVATE

    Trop-2 mRNA Expression and Association with Clinical Outcomes with Sacituzumab Govitecan in Patients with HR+/HER2– Metastatic Breast Cancer: Biomarker Results from the Phase 3 TROPiCS-02 Study

    • Author(s): Bardia, A
    • trodelvy
    • Oncology
    • Poster
    • Trop-2
    • SG
    • Trodelvy
    • Sacituzumab
    • HR+
    • HR+/HER2-
    • Biomarker
    • TROPiCS-02

    ASCENT-05/OptimICE-RD (AFT-65): Phase 3, Randomized, Open-label Study of Adjuvant Sacituzumab Govitecan + Pembrolizumab vs Pembrolizumab ± Capecitabine in Patients with TNBC and Residual Disease after Neoadjuvant Therapy and Surgery

    • Author(s): Tolaney, S
    • trodelvy
    • Oncology
    • Poster
    • ASCENT
    • AFT-65
    • Sacituzumab
    • SG
    • Trodelvy
    • TNBC
    • Neoadjuvant

    Safety Analysis by UGT1A1 Status of TROPHY-U-01 Cohort 1, a Phase 2 Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Cancer Who Progressed After Platinum-Based Chemotherapy and a Checkpoint Inhibitor

    • Author(s): Loriot, Y
    • trodelvy
    • Oncology
    • Poster
    • UGT1A1
    • TROPHY
    • Cohort 1
    • SG
    • Sacituzumab
    • Trodelvy
    • mUC
    • Bladder Cancer
    • Checkpoint
    • CPI

    TROPHY-U-01 Cohort 4: Sacituzumab Govitecan in Combination with Cisplatin as First-Line Therapy, Followed by Maintenance Avelumab + Sacituzumab Govitecan or Zimberelimab + Sacituzumab Govitecan in Patients

    • Author(s): Ramamurthy, C
    • trodelvy
    • Oncology
    • Poster
    • TROPHY
    • Cohort 4
    • SG
    • Trodelvy
    • Sacituzumab
    • Combination
    • mUC
    • Bladder Cancer

    STAR-121: A Phase 3, Randomized Study of Domvanalimab and Zimberelimab in Combination with Chemotherapy vs Pembrolizumab and Chemotherapy in Patients with Untreated Metastatic Non-Small CellLlung Cancer with No Actionable Gene Alterations (TiP)

    • Author(s): Rodriguez-Abreu, D
    • domvanalimab
    • Oncology
    • Poster
    • STAR-121
    • domvanalimab
    • zimberelimab
    • NSCLC
    • Gene alteration

    VELOCITY-Lung: A Phase 2 Study Evaluating Safety and Efficacy of Domvanalimab (Dom) + Zimberelimab (Zim) + Sacituzumab Govitecan (SG), or Etrumadenant (Etruma) + Dom + Zim, or Etruma + Zim in Patients with Treatment-Naïve Metastatic

    • Author(s): Spira, A
    • trodelvy
    • Oncology
    • Poster
    • VELOCITY
    • Lung
    • SG
    • Trodelvy
    • Sacituzumab
    • domvanalimab
    • NSCLC
    • First line
    • 1L

    A Phase 2 Multi-Arm Study of Magrolimab in Combination with Docetaxel in Patients with Locally Advanced or Metastatic Solid Tumors (ELEVATE Lung and UC) (TiP)

    • Author(s): Subbiah, V
    • magrolimab
    • Oncology
    • Poster
    • Magro
    • magrolimab
    • ELEVATE
    • Lung
    • UC
    • Bladder
    • Urothelial